Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | FABP4 | P15090 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716313 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL29688873 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL6798286 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL4343443 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL6798288 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL8025562 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL2905125 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL6051176 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL21213994 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 | |
| SCHEMBL4343438 | 1.00 | OXER1 (0.73) | OXER1MEN1KMT2AMAPTLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704797-A1 | OXYLIPINS IN THE TREATMENT OF SEBORRHEA | Pierre Fabre Dermo-Cosmétique (FR) | 2026-03-11 | — | — | EP | claimed |
| EP-4687496-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2026-02-11 | — | — | EP | claimed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| WO-2024227714-A1 | OXYLIPINS IN THE TREATMENT OF SEBORRHEA | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2024-11-07 | — | — | WO | claimed |
| WO-2024200855-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2024-10-03 | — | — | WO | claimed |
| EP-4437858-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2024-10-02 | — | — | EP | claimed |
| CN-118714935-A | Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment | 阿马里纳药物爱尔兰有限公司 | 2024-09-27 | — | — | CN | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| CN-115337401-A | Application of substance for inhibiting expression quantity and/or activity of lipoxygenase in reducing heart ischemia-reperfusion injury | 天津医科大学 | 2022-11-15 | — | — | CN | claimed |
| US-20190231730-A1 | TREATMENT OF A DISEASE MEDIATED BY ARACHIDONIC ACID OR AN EICOSANOID | GADAMIAN ROBERT (US) | 2019-08-01 | — | — | US | claimed |
| WO-2018017578-A1 | TREATMENT OF A DISEASE MEDIATED BY ARACHIDONIC ACID OR AN EICOSANOID | GADAMIAN ROBERT (US) | 2018-01-25 | — | — | WO | claimed |
| US-20160040126-A1 | REGULATION OF DIFFERENTIATION INTO DOPAMINERGIC NEURONS BY METALLOPROTEASE | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2016-02-11 | — | — | US | claimed |
| US-20130131140-A1 | TREATMENT OF DIABETES AND DISORDERS ASSOCIATED WITH VISCERAL OBESITY WITH INHIBITORS OF HUMAN ARACHIDONATE 12 LIPOXYGENASE AND ARACHIDONATE 15-LIPOXYGENASE | NADLER JERRY L (US) | 2013-05-23 | — | — | US | claimed |
| WO-2011088322-A1 | TREATMENT OF DIABETES AND DISORDERS ASSOCIATED WITH VISCERAL OBESITY WITH INHIBITORS OF HUMAN ARACHIDONATE 12 LIPOXYGENASE AND ARACHIDONATE 15-LIPOXYGENASE | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-07-21 | — | — | WO | claimed |
| WO-1999004783-A1 | COMPOSITION FOR PROTECTION FROM DAMAGE BY ISCHEMIA | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-02-04 | — | — | WO | claimed |
| US-5766571-A | Method of treating human breast cancer by administration of radiolabeled antibody and unsaturated fatty acids | CANCER RESEARCH FUND OF CONTRA COSTA (US) | 1998-06-16 | — | — | US | claimed |
| EP-4739297-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739300-A1 | MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-0065874-A1 | 2-Aminophenol derivatives, methods for their preparation and composition containing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-12-01 | — | — | EP | disclosed |
| EP-0038160-A1 | Quinone compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231730-A1 | TREATMENT OF A DISEASE MEDIATED BY ARACHIDONIC ACID OR AN EICOSANOID | PTGER1, HPGDS, PTGER4 | OXER1 78/4885MEN1 3643/4885KMT2A 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.